Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.
Research and practice in thrombosis and haemostasis
View this publicationResearch and practice in thrombosis and haemostasis
View this publicationNature
View this publicationJournal of the American Chemical Society
View this publicationImmunity
View this publicationImmunity
View this publicationEuropean urology
View this publicationJournal of the American College of Cardiology
View this publicationFrontiers in immunology
View this publicationJACC. Cardiovascular interventions
View this publicationJACC. Cardiovascular interventions
View this publication